<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04224415</url>
  </required_header>
  <id_info>
    <org_study_id>Anti-EGFR Re-challenge</org_study_id>
    <nct_id>NCT04224415</nct_id>
  </id_info>
  <brief_title>Re-challenge of Anti-EGFR for Patients With RAS/BRAF Wild-type Metastatic CRC</brief_title>
  <official_title>Re-challenge of Anti-EGFR Agents for Chinese Patients With RAS/BRAF Wild-type Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhong Li</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the trial is to study the efficacy and safety of Cetuximab re-challenge for&#xD;
      Chinese Patients with RAS/BRAF wild-type Metastatic Colorectal Cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After first-line treatment of FOLFOX/FOLFIRI/FOLFOXIRI plus Cetuximab failure and defined as&#xD;
      RAS/BRAF wild-type by molecular detection of cycle tumor DNA, the patients will be treated&#xD;
      with Cetuximab and Irinotecan as a second-line or third-line treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 31, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>Up to 2-4 months</time_frame>
    <description>defined as complete remission rates and partial remission rates after treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progress-free Survival(PFS)</measure>
    <time_frame>Up to 2-4 months</time_frame>
    <description>defined as the period from the date of receiving treatment to disease progress caused by any reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival(OS)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>defined as the period from the date of receiving treatment to death caused by any reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events(AE) and severe adverse events(SAE)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>defined as the incidence and severity of adverse events related to chemotherapy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>C225+CPT-11</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will receive Systemic C225+CPT-11 every 14 days:&#xD;
C225 500 mg/m2 IV over 90 minutes on Day 1; Irinotecan 180 mg/m2 IV on Day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C225+CPT-11</intervention_name>
    <description>Patients will receive Systemic C225+CPT-11 every 14 days:&#xD;
C225 500 mg/m2 IV over 90 minutes on Day 1; Irinotecan 180 mg/m2 IV on Day 1</description>
    <arm_group_label>C225+CPT-11</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 and ≤75.&#xD;
&#xD;
          -  Diagnosed as colorectal adenocarcinoma by histology.&#xD;
&#xD;
          -  Initially confirmed as RAS/BRAF wild type by tissue molecular detection.&#xD;
&#xD;
          -  Treated with first-line therapy of FOLFOX/FOLFIRI/FOLFOXIRI+Cetuximab effectively and&#xD;
             the PFS is not less than 6 months.&#xD;
&#xD;
          -  Tumor progression during Cetuximab treatment or after treatment within 3 months.&#xD;
&#xD;
          -  Tumor progression again after second-line treatment.&#xD;
&#xD;
          -  The interval time of re-challenge is more than 4 months after the last time treated&#xD;
             with Cetuximab.&#xD;
&#xD;
          -  Lesions can be measured by the standard of RECIST v1.1.&#xD;
&#xD;
          -  Defined as RAS/BRAF wild-type by molecular detection of cycle tumor DNA,&#xD;
&#xD;
          -  No hematologic dysfunction(Platelets &gt;90×10^9/L; WBC &gt;3×10^9/L; Neutrophil&#xD;
             &gt;1.5×10^9/L；Hemoglobin &gt;10 g/100ml).&#xD;
&#xD;
          -  Serum bilirubin ≤ 1.5 × ULN; aminotransferase ≤ 5 × ULN.&#xD;
&#xD;
          -  No ascites; no coagulation dysfunction; albumin ≥ 30g/L.&#xD;
&#xD;
          -  Hepatic function was classified as class A by Child-Pugh classification.&#xD;
&#xD;
          -  Serum creatinine &lt; 1 × ULN, or creatinine clearance rate(CCR) &gt; 50ml/ min(calculated&#xD;
             by Cockcroft-Gault formula).&#xD;
&#xD;
          -  ECOG scored as 0-2.&#xD;
&#xD;
          -  Life expectancy &gt; 3 months.&#xD;
&#xD;
          -  Informed consent.&#xD;
&#xD;
          -  Willing and able to receive follow-up until death or trial is finished or trial is&#xD;
             terminated.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  RAS/BRAF mutation.&#xD;
&#xD;
          -  Severe arterial embolism or ascites.&#xD;
&#xD;
          -  Presence of hemorrhagic tendency or coagulation dysfunction.&#xD;
&#xD;
          -  Presence of hypertensive crisis or hypertensive encephalopathy.&#xD;
&#xD;
          -  Severe uncontrolled systemic complications, such as infection or diabetes.&#xD;
&#xD;
          -  Severe clinical CVD(cardiovascular disease), such as cerebrovascular accident(within 6&#xD;
             months before recruitment), myocardial infarction(within 6 months before recruitment),&#xD;
             uncontrolled hypertension; unstable angina pectoris; congestive heart-failure(NYHA 2-4&#xD;
             grade); arrhythmia that needs medication treatment.&#xD;
&#xD;
          -  Previous diagnosed or physical examination showed presence of central nervous&#xD;
             system(CNS) disease(i.e. primary brain tumor, epilepsy uncontrolled by standard&#xD;
             treatment, any history of brain metastases or stroke).&#xD;
&#xD;
          -  Previous history of other malignancy within 5 years(except basal cell carcinoma after&#xD;
             radical resection and/or cervical carcinoma in situ).&#xD;
&#xD;
          -  Received any medication under research within 28 days before the trial.&#xD;
&#xD;
          -  Any residual toxicity of previous chemotherapy(except hair loss), i.e. peripheral&#xD;
             neuropathy ≥ NCI CTC v3.0 Grade 2, will be excluded from oxaliplatin-based&#xD;
             chemotherapy regimen research pair.&#xD;
&#xD;
          -  Allergic to any medication involved in the trial.&#xD;
&#xD;
          -  Pregnant and lactating women.&#xD;
&#xD;
          -  Patient who does not use or refuses to take any appropriate contraceptive measures&#xD;
             (intrauterine contraceptive ring, barrier contraception combined with spermicidal gel&#xD;
             or sterilization operation), including women of childbearing age (within 2 years after&#xD;
             the last menstrual period) and men who are with possible fertility.&#xD;
&#xD;
          -  Unable or unwilling to comply with the research plan.&#xD;
&#xD;
          -  The existence of any other disease, dysfunction caused by metastatic lesions, or&#xD;
             suspicious disease found on the regular examination, which indicating&#xD;
             contraindications to the use of study drugs or may bring high risks of treatment&#xD;
             related complications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 8, 2020</study_first_submitted>
  <study_first_submitted_qc>January 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>January 15, 2020</last_update_submitted>
  <last_update_submitted_qc>January 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Yuhong Li</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

